According to the statement, the Envisia classifier is the first commercially available test that could help distinguish IPF from other ILDs, without the need for surgery.
The Envisia classifier recently received Medicare coverage, making it the first test of its kind for improving IPF diagnosis to be covered for the nation's 55 million Medicare patients.
Price: 25.13, Change: +0.06, Percent Change: +0.24
|2019 Estimate for United States Steel Raised but 202...|
|58.com's 2019 Estimate Scaled Up but Q3, and 2020 Pr...|
|2019, 2020, and Q3 Earnings Estimates for W&T Of...|
|Virtusa's 2020, 2021, and Q2 Earnings Estimates Lowered|
|2019 Estimate for Vornado Realty Trust Raised but 20...|